The present disclosure discloses a human sDR5-Fc fusion protein in the preparation of adjuvant therapy for myocardial ischemia-reperfusion injury. The sDR5-Fc antibody fusion protein of the disclosure is prepared by connecting the 182 amino acids in DR5 extracellular domain with the human anti-Fc fragments. It has been tested that the sDR5-Fc antibody fusion protein of the disclosure can basically avoid Fc-mediated ADCC effect and can significantly reduce the area of myocardial infarction in rats of myocardial ischemia-reperfusion models. The disclosure has great potential for development as a candidate drug for the preparation of new drugs for the treatment of myocardial ischemia-reperfusion injury.
